Cargando…

Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals

The South African national treatment programme includes nucleoside reverse transcriptase inhibitors (NRTIs) in both first and second line highly active antiretroviral therapy regimens. Mutations in the RNase H domain have been associated with resistance to NRTIs but primarily in HIV-1 subtype B stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngcapu, Sinaye, Theys, Kristof, Libin, Pieter, Marconi, Vincent C., Sunpath, Henry, Ndung’u, Thumbi, Gordon, Michelle L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707537/ https://www.ncbi.nlm.nih.gov/pubmed/29117130 http://dx.doi.org/10.3390/v9110330

Ejemplares similares

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
por: Ariën, Kevin K, et al.
Publicado: (2011)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

HIV-1 subtype C envelope characteristics associated with divergent rates of chronic disease progression
por: Archary, Derseree, et al.
Publicado: (2010)

The KT Jeang retrovirology prize 2023: Thumbi Ndung’u
por: Ndung’u, Thumbi
Publicado: (2023)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Genetic determinants of Nef-mediated CD4 and HLA class I down-regulation differences between HIV-1 subtypes B and C
por: Mann, Jaclyn K., et al.
Publicado: (2015)

Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases
por: Marfatia, Yogesh S., et al.
Publicado: (2014)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
por: Vanangamudi, Murugesan, et al.
Publicado: (2023)

Coordination between the polymerase and RNase H activity of HIV-1 reverse transcriptase
por: Figiel, Małgorzata, et al.
Publicado: (2017)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance
por: Galilee, Meytal, et al.
Publicado: (2018)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
por: Dąbrowska, Aleksandra, et al.
Publicado: (2018)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
por: Stachowicz-Kuśnierz, Anna, et al.
Publicado: (2023)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
por: Fernandes, Lívia da Rocha, et al.
Publicado: (2023)

Retron reverse transcriptase termination and phage defense are dependent on host RNase H1
por: Palka, Christina, et al.
Publicado: (2022)

Endogenous reverse transcriptase and RNase H-mediated antiviral mechanism in embryonic stem cells
por: Wu, Junyu, et al.
Publicado: (2021)

Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that may promote reproductive health
por: Munoz, Alexander, et al.
Publicado: (2021)

Correction to: Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that may promote reproductive health
por: Munoz, Alexander, et al.
Publicado: (2021)

HIV-1 vaccine immunogen design strategies
por: Mann, Jaclyn K, et al.
Publicado: (2015)

The potential of lactoferrin, ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-19
por: Mann, Jaclyn Kelly, et al.
Publicado: (2020)

Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition
por: Jones, R. Brad, et al.
Publicado: (2008)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Schauer, Grant, et al.
Publicado: (2013)

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
por: Usach, Iris, et al.
Publicado: (2013)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
por: Wright, David W., et al.
Publicado: (2012)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
por: Zhuang, Chunlin, et al.
Publicado: (2020)

Prodrugs of γ‐Alkyl‐Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase
por: Zhao, Chenglong, et al.
Publicado: (2020)

Prevalence and seasonality of common viral respiratory pathogens, including Cytomegalovirus in children, between 0–5 years of age in KwaZulu-Natal, an HIV endemic province in South Africa
por: Famoroti, Temitayo, et al.
Publicado: (2018)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
por: Dwivedi, Richa, et al.
Publicado: (2022)

Trans-lesion synthesis and RNaseH activity by reverse transcriptases on a true abasic RNA template
por: Küpfer, Pascal A., et al.
Publicado: (2007)

Influence of the RNase H domain of retroviral reverse transcriptases on the metal specificity and substrate selection of their polymerase domains
por: Talele, Tanaji T, et al.
Publicado: (2009)

Free Energy-Based Virtual Screening and Optimization of RNase H Inhibitors of HIV-1 Reverse Transcriptase
por: Zhang, Baofeng, et al.
Publicado: (2016)

Genetic Characteristics, Coreceptor Usage Potential and Evolution of Nigerian HIV-1 Subtype G and CRF02_AG Isolates
por: Ajoge, Hannah O., et al.
Publicado: (2011)

Abstracts from the current global literature: Mitochondrial toxicities due to nucleoside reverse transcriptase inhibitors
por: Jain, Sonia, et al.
Publicado: (2012)

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance
por: Garforth, Scott J., et al.
Publicado: (2014)

Nucleoside reverse transcriptase inhibitor-induced rat oocyte dysfunction and low fertility mediated by autophagy
por: Tang, Li, et al.
Publicado: (2017)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
por: Petrou, Anthi, et al.
Publicado: (2019)

Synthesis and molecular docking studies of quinoline derivatives as HIV non-nucleoside reverse transcriptase inhibitors
por: BHARDWAJ, Nivedita, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6q2j6obie21agruer14juq7ikj